Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$23.58 USD
+0.35 (1.51%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $25.50 +1.92 (8.14%) 6:36 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/12/2025
Time: -- |
9/2025 | $-0.38 | -4.00% |
Earnings Summary
For their last quarter, Structure Therapeutics Inc. Sponsored ADR (GPCR) reported earnings of -$0.36 per share, missing the Zacks Consensus Estimate of -$0.28 per share. This reflects a negative earnings surprise of 28.57%. Look out for GPCR's next earnings release expected on November 12, 2025. For the next earning release, we expect the company to report earnings of -$0.38 per share, reflecting a year-over-year decrease of 90%.
Earnings History
Price & Consensus
Zacks News for GPCR
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
GPCR FAQs
Based on past history, Zacks believes Structure Therapeutics Inc. Sponsored ADR (GPCR) will report their next quarter earnings on November 12, 2025. For the next earning release, we expect the company to report earnings of -0.38 per share, reflecting a year-over-year increase of -90.00.
Based on past history, Zacks believes Structure Therapeutics Inc. Sponsored ADR (GPCR) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 12, 2025.
The Zacks Consensus Estimate for Structure Therapeutics Inc. Sponsored ADR (GPCR) for the quarter ending in September 2025 is $-0.38 a share. We expect Structure Therapeutics Inc. Sponsored ADR to miss by -4.00%.
In the earnings report for the quarter ending in June 2024, Structure Therapeutics Inc. Sponsored ADR (GPCR) announced earnings of $-0.18 per share versus the Zacks Consensus Estimate of $-0.23 per share, representing a surprise of -21.74%.